News

News of LinkZill

2024-10-25

LinkZill Secures Several Million Dollars in Series A Financing to Accelerate Life Science Product Delivery and Fuel Global Market Expansion

2023-11-28 | 36Kr

What’s the madness behind growing DNA on "cell phone screens" ?

2022-02-14 | SJTU XIN SHANG YUAN

SJTU Ph.D. Founder: After Three Years in the Dark, Now Aims to Capture the Trillion-Yuan TFT Biochip Market

2022-08-11 | SynBio

Entering the Trillion-Yuan Biochip Market with TFT-Based High-Throughput DNA Synthesis and Digital Microfluidics to Build an Integrated Chip Experiment Platform

Dr. Kang Kang

Partner & CBio

Dr. Kang received his Ph.D. in Bioinformatics and Systems Biology from the University of Hong Kong in 2018, then became a scientific co-worker of the Leibniz Association (Leibniz-HKI) and a visiting scientist at the Novo Nordisk Foundation Center for Biosustainability (DTU Biosustain) at the Technical University of Denmark. He was a scientist at BGI-Shenzhen and co-founded the synthetic biology research group. He was a senior bioinformatics engineer and brand advisor at WeGene. In 2021, Kang joined Biosysen Limited as a co-founder and served as Chief Informatics Scientist. He is also an advisor and author of the biotech media "Regenesis". He has been dedicated to the R&D and industrialization of OMICs technologies, high-throughput technologies, and synthetic biology for over 10 years. He joined LinkZill in March 2023, responsible for semiconductor life science tools and product planning.

康康   博士

合伙人兼首席生物信息官

博士毕业于香港大学生物信息和系统生物学专业,后任德国莱布尼茨协会科学合作者、丹麦科技大学诺和诺德生物可持续研究中心访问科学家。曾先后担任华大基因科学家,参与创立了华大基因合成生物学研究方向;微基因资深生物信息工程师、品牌顾问;倍生生物联合创始人兼首席信息科学家。他专注于合成生物学、组学和高通量技术10余年,同时也是生物技术领域颇具影响力的「行业KOL」。2023年3月加入领挚科技,负责半导体生命科学工具方向与产品规划。